Brendan F Gilmore
Brendan F Gilmore
Bestätigte E-Mail-Adresse bei qub.ac.uk
Titel
Zitiert von
Zitiert von
Jahr
Clinical relevance of the ESKAPE pathogens
JN Pendleton, SP Gorman, BF Gilmore
Expert review of anti-infective therapy 11 (3), 297-308, 2013
7752013
Alternatives to antibiotics—a pipeline portfolio review
L Czaplewski, R Bax, M Clokie, M Dawson, H Fairhead, VA Fischetti, ...
The Lancet infectious diseases 16 (2), 239-251, 2016
4802016
Staphylococcus epidermidis device‐related infections: pathogenesis and clinical management
MT McCann, BF Gilmore, SP Gorman
Journal of Pharmacy and Pharmacology 60 (12), 1551-1571, 2008
2672008
Antibiofilm activities of 1-alkyl-3-methylimidazolium chloride ionic liquids
L Carson, PKW Chau, MJ Earle, MA Gilea, BF Gilmore, SP Gorman, ...
Green Chemistry 11 (4), 492-497, 2009
2422009
Hugo and Russell's pharmaceutical microbiology
SP Denyer, NA Hodges, SP Gorman
John Wiley & Sons, 2008
2122008
Eradication of Pseudomonas aeruginosa biofilms by atmospheric pressure non-thermal plasma
MY Alkawareek, QT Algwari, G Laverty, SP Gorman, WG Graham, ...
PloS one 7 (8), e44289, 2012
1692012
The use of lytic bacteriophages in the prevention and eradication of biofilms of Proteus mirabilis and Escherichia coli
L Carson, SP Gorman, BF Gilmore
FEMS Immunology & Medical Microbiology 59 (3), 447-455, 2010
1632010
The potential of antimicrobial peptides as biocides
G Laverty, SP Gorman, BF Gilmore
International journal of molecular sciences 12 (10), 6566-6596, 2011
1612011
Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy
EM Ryan, SP Gorman, RF Donnelly, BF Gilmore
Journal of Pharmacy and Pharmacology 63 (10), 1253-1264, 2011
1552011
Antimicrobial and antibiofilm activities of 1-alkylquinolinium bromide ionic liquids
A Busetti, DE Crawford, MJ Earle, MA Gilea, BF Gilmore, SP Gorman, ...
Green Chemistry 12 (3), 420-425, 2010
1322010
Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro
EM Ryan, MY Alkawareek, RF Donnelly, BF Gilmore
FEMS Immunology & Medical Microbiology 65 (2), 395-398, 2012
1232012
Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection
SM Abdelghany, DJ Quinn, RJ Ingram, BF Gilmore, RF Donnelly, ...
International journal of nanomedicine 7, 4053, 2012
1232012
Potential cellular targets and antibacterial efficacy of atmospheric pressure non-thermal plasma
MY Alkawareek, SP Gorman, WG Graham, BF Gilmore
International journal of antimicrobial agents 43 (2), 154-160, 2014
1222014
Application of ω-transaminases in the pharmaceutical industry
SA Kelly, S Pohle, S Wharry, S Mix, CCR Allen, TS Moody, BF Gilmore
Chemical reviews 118 (1), 349-367, 2018
1112018
Biomolecular mechanisms of Pseudomonas aeruginosa and Escherichia coli biofilm formation
G Laverty, SP Gorman, BF Gilmore
Pathogens 3 (3), 596-632, 2014
1082014
The antimicrobial potential of ionic liquids: A source of chemical diversity for infection and biofilm control
JN Pendleton, BF Gilmore
International journal of antimicrobial agents 46 (2), 131-139, 2015
982015
Antimicrobial activity of short, synthetic cationic lipopeptides
G Laverty, M McLaughlin, C Shaw, SP Gorman, BF Gilmore
Chemical biology & drug design 75 (6), 563-569, 2010
972010
Application of atmospheric pressure nonthermal plasma for the in vitro eradication of bacterial biofilms
MY Alkawareek, QT Algwari, SP Gorman, WG Graham, D O'Connell, ...
FEMS Immunology & Medical Microbiology 65 (2), 381-384, 2012
952012
Microbiological interactions with cold plasma
P Bourke, D Ziuzina, L Han, PJ Cullen, BF Gilmore
Journal of applied microbiology 123 (2), 308-324, 2017
902017
Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with …
J Deacon, SM Abdelghany, DJ Quinn, D Schmid, J Megaw, RF Donnelly, ...
Journal of controlled release 198, 55-61, 2015
862015
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20